The earnings call highlighted positive developments with the FDA and interest from the medical community, as well as regional sales growth in North America and Europe. However, the company continues to face challenges with overall revenue and profit margins declining, and it remains in a net loss position. Financial support from a major shareholder provides some stability as they await regulatory decisions.

Company Guidance -

Q2 2025

During the conference call, IceCure Medical Ltd provided guidance regarding its anticipated milestones and financial expectations. The company highlighted the submission of a post-market study plan to the FDA, which is pivotal for gaining marketing authorization for their ProSense system aimed at treating early-stage low-risk breast cancer in women aged seventy and above, representing a demographic of approximately 46,000 patients annually in the U.S. The study will involve a minimum of 400 patients across 25 sites, with recruitment expected within three years. Financially, IceCure reported a revenue of $725,000 for Q1 2025, slightly down from $743,000 in Q1 2024, with a gross margin of 30%, compared to 36% the previous year. Operating expenses slightly decreased to $3.88 million from $3.92 million, and the net loss was $3.59 million or $0.06 per share, compared to $3.61 million or $0.08 per share last year. The company had cash and cash equivalents of approximately $6.2 million as of May 27, 2025, including a $2 million unsecured bridge loan from Epoch. IceCure plans to scale its U.S. sales team following FDA approval and expand reimbursement opportunities, potentially transitioning from a CPT3 to a CPT1 code.

Positive FDA Meeting Outcome

IceCure Medical had a positive high-level meeting with the FDA, leading to a request for a post-market study plan, which is seen as a positive signal for ProSense marketing authorization.

Interest from Medical Community

There was significant interest in ProSense at the American Society of Breast Surgeons 2025 meeting, with many surgeons expressing interest in participating in the post-market study.

Strong Regional Sales Growth

Revenue in North America increased by 11% and in Europe by 60% year-over-year despite an overall slight decline in total revenue.

Financial Support from Largest Shareholder

The company secured a $2 million unsecured loan from its largest shareholder, providing financial flexibility while awaiting FDA decisions.

Icecure Medical (ICCM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ICCM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 18, 2025	2025 (Q2)	-0.06 / -	-0.06	―	―	―
May 28, 2025	2025 (Q1)	-0.08 / -0.06	-0.08	25.00% (+0.02)	―
Mar 27, 2025	2024 (Q4)	-0.07 / -0.08	-0.06	-33.33% (-0.02)	―
Nov 26, 2024	2024 (Q3)	-0.07 / -0.08	-0.09	11.11% (<+0.01)	―
Aug 20, 2024	2024 (Q2)	-0.07 / -0.06	-0.09	33.33% (+0.03)	―
May 28, 2024	2024 (Q1)	- / -	-0.083	―	―
Apr 03, 2024	2023 (Q4)	-0.08 / -0.08	-0.08	0.00% (0.00)	―
Nov 15, 2023	2023 (Q3)	-0.09 / -0.09	-0.11	18.18% (+0.02)	―
Aug 14, 2023	2023 (Q2)	-0.09 / -0.09	-0.12	25.00% (+0.03)	―
May 22, 2023	2023 (Q1)	-0.09 / -0.08	0.12	-166.67% (-0.20)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ICCM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 28, 2025	$1.13	$1.03	-8.85%
Mar 27, 2025	$1.14	$1.10	-3.51%
Nov 26, 2024	$0.78	$0.79	+1.28%
Aug 20, 2024	$0.64	$0.75	+17.19%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does IceCure Medical (ICCM) report earnings?

IceCure Medical (ICCM) is schdueled to report earning on Aug 18, 2025, TBA (Confirmed).

What is IceCure Medical (ICCM) earnings time?

IceCure Medical (ICCM) earnings time is at Aug 18, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ICCM EPS forecast?

ICCM EPS forecast for the fiscal quarter 2025 (Q2) is -0.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing